# LLY earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/LLY) · [Earnings tab](https://www.lopjlb.com/stock/LLY?tab=earnings)

Updated: 2026-10-05T06:03:44

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of Lilly earnings CallCards, revenue growth accelerated from 42% in Q3 2024 to a peak of 56% in Q1 2026, reflecting expanding sales of Mounjaro, Zepbound and new launches such as Foundayo. Demand for incretin and obesity products remained strong, but visibility was repeatedly clouded by supply‑chain volatility, channel inventory swings and pricing pressure from formulary exclusions and Medicaid cuts. Manufacturing capacity was repeatedly highlighted as a growth lever, with multiple new sites and capacity upgrades announced and largely on‑track. The regulatory pipeline accelerated, delivering a cascade of approvals (Kisunla, Omvoh, Orforglipron, Retatrutide, Foundayo) and advancing late‑stage trials, while some assets (TRIUMPH‑1, certain obesity trials) remained at risk. Competitive dynamics intensified as generic semaglutide entered markets and oral GLP‑1 candidates emerged, prompting recurring concerns about market‑share erosion. Throughout, shareholder return programs persisted, but pricing and reimbursement headwinds grew, especially in the US Medicaid environment. Overall, the narrative shifted from managing short‑term supply constraints to scaling manufacturing, broadening the pipeline, and navigating a more complex pricing and competitive landscape.

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2026 Q1:** Lilly reports 56% Q1 revenue growth, FDA approval of oral GLP-1 Foundayo, strong obesity product momentum and raises full-year revenue guidance to $82-$85 bn.
- **2025 Q4:** Lilly reports 45% revenue growth, strong product launches and manufacturing expansion, while flagging pricing pressure and Medicaid coverage risks ahead of 2026 guidance.
- **2025 Q3:** Lilly reports 54% revenue growth in Q3 2025, raises full-year guidance to $63-63.5B, advances orforglipron toward global submissions, expands manufacturing footprint, and progresses pipeline across cardiometabolic, oncology, neuroscience, and immunology.
- **2025 Q2:** Lilly reported 38% revenue growth, raised 2025 guidance, announced positive Phase III data for orforglipron and tirzepatide, but noted pricing and formulary headwinds.
- **2025 Q1:** —
- **2024 Q4:** Lilly posted 45% Q4 revenue growth driven by Mounjaro and Zepbound, expanded manufacturing, delivered new approvals and set 2025 guidance assuming continued prescription growth.
- **2024 Q3:** Lilly reported 42% revenue growth driven by Mounjaro and Zepbound, strong new‑product sales, multiple approvals and data readouts, while highlighting supply‑linked channel volatility and upcoming demand‑generation ramps.

## Theme arcs

- **Revenue growth** (improving): Growth rose from low‑40% to mid‑50% YoY as new products launched
- **Incretin demand** (stable): Strong demand persisted despite channel inventory volatility
- **Pricing pressure** (deteriorating): Formulary exclusions, Medicaid cuts and PBM fee shifts compressed net pricing
- **Supply chain volatility** (deteriorating): Channel inventory swings and cold‑chain limits repeatedly cited
- **Manufacturing capacity expansion** (improving): Multiple new sites and capacity upgrades announced and on‑track
- **Regulatory pipeline** (improving): Series of approvals and late‑stage trial readouts accelerated
- **Competitive intensity** (deteriorating): Generic semaglutide launches and oral GLP‑1 entrants raised share risk
- **AI/tech collaborations** (new): Partnerships with OpenAI and NVIDIA introduced
- **Shareholder returns** (stable): Ongoing dividends and share repurchases
- **Guidance outlook** (improving): Guidance moved from maintained to raised in successive quarters

## Fear persistence

- **Pricing/reimbursement risk** [recurring]: Formulary exclusions, Medicaid cuts and net‑price erosion cited each quarter
- **Supply chain risk** [recurring]: Channel inventory volatility and cold‑chain constraints repeatedly noted
- **Compounding safety/legal risk** [recurring]: Litigation and safety concerns over unauthorized compounding mentioned multiple times
- **Payer coverage uncertainty** [recurring]: Medicare/Medicaid and employer coverage decisions affect obesity product uptake
- **Competitive pressure** [recurring]: Generic semaglutide entry and oral GLP‑1 launches create share‑loss risk
- **Regulatory/tariff uncertainty** [recurring]: FDA capacity, tariff environment and pending approvals flagged
- **Medicaid coverage reduction** [recurring]: State cuts (e.g., California) highlighted as demand headwinds

## Guidance path

2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:raised → 2025 Q3:raised → 2025 Q4:raised → 2026 Q1:raised → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/LLY`